BioStock takes a closer look at Curasight´s potential in brain cancer

Danish Curasight develops its drug candidates uTRACE and uTREAT for diagnosis and treatment of several cancer indications. BioStock recently took a closer look at the potential seen in prostate cancer, and in this article we will dive deeper into the company´s ambitions within glioblastoma. With phase IIb results pending, preparations for phase III with uTRACE are being made, all while advancing the preclinical uTREAT project.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/02/biostock-takes-a-closer-look-at-curasights-potential-in-brain-cancer/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se